Truist Cuts Elevance Health (ELV) Price Target, Keeps Bullish View on Healthcare Services

Elevance Health, Inc. (NYSE:ELV) is included among the 10 Healthcare Stocks with Highest Dividends.

On April 13, Truist lowered its price recommendation on Elevance Health, Inc. (NYSE:ELV) to $375 from $390. It reiterated a Buy rating on the shares. The change came as part of a broader Q1 preview for Healthcare Services. The firm still takes a positive view on the sector. It points to steady demand, long-term structural tailwinds, and a reimbursement environment that looks more stable. The recent Final Medicare Advantage Rule was described as an “encouraging data point,” according to the analyst. Truist also noted that the group benefits from its scale and domestic focus. It sees the sector as defensive in nature. At the same time, companies are gaining from AI, automation, and better connectivity across systems. Strong free cash flow and financial flexibility are expected to support continued investment, M&A activity, and shareholder returns.

On April 8, Evercore ISI analyst Elizabeth Anderson initiated coverage of Elevance Health with an In Line rating and a $345 price target. The firm described Elevance as a diversified managed care company with “resilient” earnings in the current environment. It suggested the company could meet or exceed its 2026 guidance. Still, there are some concerns. Evercore sees downside risk to 2027 estimates. It also flagged a “meaningful likelihood” that the One Big Beautiful Bill work requirements could trigger “another wave of rate-acuity mismatch” in Medicaid.

Elevance Health, Inc. (NYSE:ELV) operates as a health insurer in the United States. The business is organized into four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

READ NEXT: 14 Value Stocks with Highest Dividends and Early Retirement Portfolio: Top 15 Stocks to Buy

Disclosure: None. Follow Insider Monkey on Google News.